Nuvectis Pharma (NVCT) Return on Equity (2021 - 2026)

Nuvectis Pharma has disclosed Return on Equity across 6 years of filings, most recently posting 0.02% for Q1 2026.

• Return on Equity for Q1 2026 came in at 0.02%, changed 0.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.02% (changed 0.0% YoY), and the FY2025 annual result was 0.02%, changed 0.0% from the prior year.
• Return on Equity came in at 0.02% for Q1 2026 at Nuvectis Pharma, down from 0.01% in the prior quarter.
• In the past five years, Return on Equity ranged from a high of 0.01% in Q3 2022 to a low of 0.09% in Q1 2022.
• The 5-year median for Return on Equity is 0.01% (2023), against an average of 0.02%.
• Across the five-year window, Return on Equity slipped 2 bps in 2022 and advanced 7 bps in 2023, its largest moves.
• Nuvectis Pharma's Return on Equity stood at 0.01% in 2022, then plunged by 40 bps to 0.02% in 2023, then slipped by 19 bps to 0.02% in 2024, then soared by 32 bps to 0.01% in 2025, then slumped by 34 bps to 0.02% in 2026.
• The last three Return on Equity figures came in at 0.02% (Q1 2026), 0.01% (Q4 2025), and 0.01% (Q3 2025), per Business Quant data.